Tiziana Life Sciences has completed dosing the last patient in its Phase 2 trial testing intranasal foralumab for early/mild Alzheimer's disease. The randomized, placebo-controlled study evaluates safety, tolerability, and efficacy of foralumab alone and combined with anti-amyloid drugs lecanemab or donanemab. Key outcomes include effects on neuroinflammation, cognitive function, and biomarkers. Topline results are expected in Q1 2027 and could establish immunomodulation as a new treatment approach for Alzheimer's.
Tiziana Life Sciences' Phase 2 trial dosing completion for intranasal foralumab in mild Alzheimer's disease comes as 95 of 150 health-sector US stocks on Pluang rose today. For readers following health-sector stocks, here is Pluang's market snapshot as of Oct 16, 2026 18:11 WIB: Inovio Pharmaceuticals Inc (INO) rose 3.85% to USD 1.08 with 55% buy orders and a typical hold time of 43 days; Cassava Sciences Inc (FLNA) fell 3.76% to USD 0.73 with a nearly balanced buy/sell split; Heron Therapeutics Inc (HRTX) rose 3.05% to USD 0.39 despite 60% sell orders and a 36-day hold time.
The Out of Home Advertising Association of America (OAAA) held the 84th Annual OBIE Awards in New York City, celebrating the best creative campaigns in out of home (OOH) advertising. Paramount was inducted into the OBIE Hall of Fame for its longstand...
NeOnc Technologies reported early clinical improvement in a critically ill three-year-old boy with an aggressive brain tumor treated with investigational intranasal NEO100 under compassionate use in Abu Dhabi. The child is now breathing independently...
TransUnion's Branded Call Display, a solution that helps consumers identify legitimate callers and avoid robocall fraud, has been named one of TIME's Best Inventions of 2026 in the Connectivity & Communication category. The technology displays a busi...
La Rosa Holdings Corp. will change its name to Stratum Holdings Corp. on October 19, 2026, reflecting its shift from real estate services to an AI infrastructure company specializing in GPU leasing and high-performance computing. The company recently...
ASUS has released the ProArt P16 and P14 laptops in Canada, powered by NVIDIA RTX Spark technology. These laptops feature up to 128GB of unified memory and advanced AI capabilities designed for creators, AI developers, and workflow builders, enabling...
